Potentially Curable Pancreatic Cancer Guideline
13 Apr, 2017 | 16:02h | UTCDue to a recent study showing a 2,5 month increase in median overall survival, the doublet regimen of gemcitabine and capecitabine seems to be preferred in the absence of concerns for toxicity or tolerance.